Email updates

Keep up to date with the latest news and content from Journal of Hematology & Oncology and BioMed Central.

Open Access Letter to the Editor

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

Ning Li1, Yongping Song1, Jian Zhou1 and Baijun Fang12*

  • * Corresponding author: Baijun Fang sunfbj@126.com

  • † Equal contributors

Author Affiliations

1 Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital affiliated to Zhengzhou University, Zhengzhou, China

2 Henan Institute of Haematology, Henan Tumor Hospital affiliated to Zhengzhou University, 127 Dongming Road, Zhengzhou, 450008, China

For all author emails, please log on.

Journal of Hematology & Oncology 2012, 5:61  doi:10.1186/1756-8722-5-61

Published: 9 October 2012

Abstract

We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was performed after an interval of one week. All patients achieved clinically significant responses to ATO. The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment with ATO may be a feasible approach in patients with refractory SAA.

Keywords:
Aplastic anemia; Hematopoiesis; Arsenic trioxide; Adipocytes; Mesenchymal stem cells